Navigation Drawer
close
Search
Light System Dark
-
Tech
-
Reviews
-
Science
-
Entertainment
-
AI
-
Policy
-
Gadgets
-
Verge Shopping
-
Gaming
-
Streaming
-
Transportation
-
Verge Video
-
Podcasts
Anthropic wants to develop its own drugs
Comments Drawer
Comments
- AI AI Posts from this topic will be added to your daily email digest and your homepage feed.
Follow See All AI
- Report Report Posts from this topic will be added to your daily email digest and your homepage feed.
Follow See All Report
- Science Science Posts from this topic will be added to your daily email digest and your homepage feed.
Follow See All Science
Anthropic wants to develop its own drugs
The AI drug boom has a long way to go before reaching patients.
The AI drug boom has a long way to go before reaching patients.
by Robert Hart
Robert Hart
AI Reporter
Posts from this author will be added to your daily email digest and your homepage feed.
Follow See All by Robert Hart
Jul 3, 2026, 1:56 PM UTC
If you buy something from a Verge link, Vox Media may earn a commission. See our ethics statement.
Image: The Verge
Robert Hart
Robert Hart
Posts from this author will be added to your daily email digest and your homepage feed.
Follow See All by Robert Hart
is a London-based reporter at The Verge covering all things AI and a Senior Tarbell Fellow. Previously, he wrote about health, science and tech for Forbes.
At the event “The Briefing: AI for Science”earlier this week, Anthropic announced Claude Science, a new “AI workbench for scientists” that pulls fragmented tools and datasets into one environment, and generates figures and visuals. Anthropic, already dominating the industry with its popular coding tools and powerful AI models, framed the launch around what it says is AI’s potential to “dramatically accelerate the pace of scientific discovery and the development of healthcare interventions,” and touted a long list of biotech and pharma customers already using Claude.
Anthropic also went a step further, saying it would develop drugs of its own. Head of life sciences Eric Kauderer-Abrams said the company will focus on discovering treatments for “neglected” diseases.
AI companies have been eager to court science and pharma customers — OpenAI, Amazon, Google, and others have their own life sciences tools and platforms. But Anthropic’s planned move is one of the most direct public attempts by a major frontier AI company to actually develop drugs itself. It puts it in the unusual position of selling software to other, potentially competing drugmakers. Anthropic joins a broader race that includes AI-first drug companies like Insilico, Google DeepMind spinout Isomorphic Labs, biotech startups, and Big Pharma companies building or buying AI tools of their own.
Anthropic has provided very few specific details about what it hopes to accomplish in the drug development space. At the event, Kauderer-Abrams didn’t say what the company would do if it finds any promising drug candidates. Anthropic did not respond to The Verge’s requests for comment seeking more details, including what diseases it plans to target first and whether it would partner up with other companies for lab work, animal testing, clinical trials, or manufacturing.
AI is applied at “every single stage of drug discovery.”
Experts told The Verge that the uncertainty surrounding Anthropic’s plans reflects a broader uncertainty around the AI drug boom itself. “AI drug discovery” can mean many things. It “is a really broad term,” explained Namshik Han, a professor at the University of Cambridge and cofounder of AI biotech startup CardiaTec. AI is applied at “every single stage of drug discovery,” he said, from finding new compounds and improving them to supporting research, data analysis, clinical trials, and even manufacturing. Every major drug company will be using AI in some way, he said. Matthew Todd, a professor of drug discovery at University College London, echoed the sentiment that AI already pervades drug discovery and research, calling it a “catchall phrase” given its broad array of uses.
Related
- Something’s off with Midjourney’s pivot to body scanners
- Claude Fable is too scared to teach you about the powerhouse of the cell
- Lawmakers want to ban AI companies from selling your health data
AI is undoubtedly changing drug development. Han pointed to the numerous initiatives by pharma giants like AstraZeneca, Novo Nordisk, and GSK, and said AI can already help generate possible drug ideas, such as by suggesting new molecules that could interact with parts of the body like cell receptors that are already known to be involved with a particular disease or are targets of existing drugs. Todd said it’s immensely useful for speeding up research and helping “road test” new drug ideas. Given Anthropic’s work on frontier models, the company would presumably use generative AI to search across vast chemical and biological possibilities and help researchers make connections that would be difficult or slow to find otherwise, potentially suggesting new drug ideas, identifying new disease targets, or finding new uses for existing drugs.
But that is still a long way from an AI-designed drug reaching patients. Todd said the field is “a long way off” from an AI-designed drug being approved by regulators for human use. He added that the drug discovery process would not run autonomously, with human input and supervision required throughout. Todd and Han both noted the lack of publicly available, high-quality experimental data, such as how various chemicals behave in the body, could slow drug development efforts as well, stressing that even for well-studied areas of biology there are still large gaps in our understanding of how things work.
AI models “haven’t yet come close to making experiments unnecessary.”
AI is not positioned to fix many of the slowest parts of drug discovery. Frank von Delft, a professor of structural chemical biology at the University of Oxford and head of protein crystallography at the Oxford Centre for Medicines Discovery, said people are right to get excited about advancing AI models, but they “haven’t yet come close to making experiments unnecessary.” Drug candidates still have to be tested in the real world for efficacy, toxicity, and whether they have practical properties allowing them to be prepared, stored, and delivered safely as medicines. All of that requires skilled workers, a lot of money, and time, especially clinical work in humans — a point when many promising drug candidates fail. If Anthropic wants to develop a drug, von Delft said, it is “going to have to spend a lot on experiments.”
It’s possible Anthropic is willing to try. In the last year, the company has been actively hiring biologists and building its own wet labs, and as of writing it has several live applications hiring for life sciences roles. Han said Anthropic has been “actively recruiting” in the area too, adding that several of his academic colleagues had been approached by the company. Without naming names, Han said he thinks Anthropic has successfully hired a few candidates away from Big Pharma and prestigious academic institutions.
With all of this complexity, whatever disease Anthropic picks, any payoff is likely a long way away — at the very least, the better part of a decade, given how long it typically takes a new drug to go through clinical trials. There’s “always a big lag time” with testing medicine, Todd said. “It takes time to show experimentally that something’s safe.” No AI-designed drug has yet made it through clinical trials and FDA approval to reach market. Some AI-developed candidates have enteredclinical trials, but it’s hard to know how much AI contributed, where in the process it was used, or whether those candidates outperform conventional drugs. AI can speed up part of the search, but drugs still need to prove themselves the old-fashioned way: in slow, methodical experiments that take place in the real world.
Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.
- Robert Hart Robert Hart AI Reporter
Posts from this author will be added to your daily email digest and your homepage feed.
Follow See All by Robert Hart
- AI AI Posts from this topic will be added to your daily email digest and your homepage feed.
Follow See All AI
- Anthropic Anthropic Posts from this topic will be added to your daily email digest and your homepage feed.
Follow See All Anthropic
- Health Health Posts from this topic will be added to your daily email digest and your homepage feed.
Follow See All Health
- Report Report Posts from this topic will be added to your daily email digest and your homepage feed.
Follow See All Report
- Science Science Posts from this topic will be added to your daily email digest and your homepage feed.
Follow See All Science
Most Popular
Most Popular
- Sony’s PlayStation disc factory is already being repurposed
- Apple TV is hitting its stride
- I finally got my Trump phone
- Weber marks down grills and griddles to their best prices ever for July 4th
- Amazon has enough satellites to launch its Starlink competitor
Video 91/1 Skip Ad Continue watching after the adVisit Advertiser websiteGO TO PAGE
The Verge Daily
A free daily digest of the news that matters most.
Email (required)
Sign Up
By submitting your email, you agree to ourTerms and Privacy Notice. This site is protected by reCAPTCHA and the GooglePrivacy PolicyandTerms of Serviceapply.
Advertiser Content From This is the title for the native ad
More in AI
A behind-the-scenes look at Midjourney’s medical scanner leaves many questions unanswered
OpenAI floats giving Trump administration 5 percent cut of AI boom
6
Verge Score
Google built a great smart speaker, but Gemini isn’t ready for it
Anthropic’s long-sidelined Fable 5 is greenlit to return
Google’s NotebookLM can sum up your research in a TikTok-style clip
Netflix is using an AI-generated Gene Wilder voice in its Willy Wonka reality show
A behind-the-scenes look at Midjourney’s medical scanner leaves many questions unanswered
Robert Hart Jul 34
OpenAI floats giving Trump administration 5 percent cut of AI boom
Robert Hart Jul 233
Google built a great smart speaker, but Gemini isn’t ready for it
Jennifer Pattison Tuohy Jul 131
Anthropic’s long-sidelined Fable 5 is greenlit to return
Hayden Field Jul 116
Google’s NotebookLM can sum up your research in a TikTok-style clip
Emma Roth Jun 3015
Netflix is using an AI-generated Gene Wilder voice in its Willy Wonka reality show
Richard Lawler Jun 3035
Advertiser Content From This is the title for the native ad
Top Stories
Jul 3
Apple TV is hitting its stride
Jul 3
Jul 3
The Verge’s annual summer ‘in’ and ‘out’ list
Jul 3
Jul 3
Hydration isn’t complicated: Just drink water
-
Do Not Sell or Share My Personal Data
© 2026Vox Media, LLC. All Rights Reserved
Notifications Drawer
Sign in to see your notifications or create an account to join the conversation.
Privacy Center
When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.
Cookie Policy Vendor List
Allow All
Manage Consent Preferences
Strictly Necessary Cookies
Essential
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
-
Functional Cookies
Essential
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
View Vendor Details
Allow the Sale or Sharing/Targeted Advertising
- Allow the Sale or Sharing/Targeted Advertising
As a valued user, we are providing you the ability to opt-out from the sharing of your personal information to advertisers and social media companies at any time across business platform, services, businesses and devices. You can opt-out of the sharing of your personal information by using this toggle switch. For more information on your rights and options see our privacy notice.
-
Performance Cookies
- Switch Label
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
-
Social Media & Embedded Content
- Switch Label
Content embedded on our sites (e.g. social media posts, video clips, polls and games) originates from third party sources such as social media platforms, video sharing sites, or other third party websites. When this content loads on pages you visit, any cookies or similar tracking technologies set by the third party source in connection with that content may also load. Vox Media doesn't set these cookies and doesn't control them. These cookies may be capable of tracking your browser across sites and/or building a profile of your interests. Not allowing these cookies will impact what content you can see and engage with on our sites.
-
Targeting Cookies
- Switch Label
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
View Vendor Details
Vendors List
Clear
-
- checkbox label label
Apply Cancel
Consent Leg.Interest
-
checkbox label label
-
checkbox label label
-
checkbox label label
Reject All Confirm My Choices